Artificial Intelligence in Next-Generation Cardiac Systems: Wearable and Implantable Technologies for Clinical Practice
Key result
Next-generation cardiac technologies show diagnostic promise, but technical capability outpaces demonstrated real-world clinical utility.
Next research. published a graphical abstract
Its licence doesn't allow us to show a copy here.
Why the study?
The evolution of cardiac technologies to implantable, wearable, and AI-enabled systems should not be assumed to represent a uniform improvement in clinical care.
Key Points
- To evaluate the clinical maturity, diagnostic accuracy, and real-world implementation readiness of contemporary AI-enabled wearable and implantable cardiac technologies.
- Conducted a critical narrative review of contemporary implantable cardiac devices, wearable sensor platforms, and AI applications in cardiovascular medicine.
- Assessed technologies across cardiac rhythm analysis, echocardiography, and longitudinal device data for evidence maturity, workflow burden, and clinical integration.
- Implantable systems deliver reliable continuous monitoring and therapy, but overall clinical benefit depends on careful patient selection, complication profiles, and infrastructure for follow-up.
- Wearable technologies expand ambulatory rhythm surveillance, but high rates of false-positive alerts, signal constraints, and downstream workflow burdens restrict real-world utility.
- AI demonstrates strong potential in electrocardiogram analysis and echocardiographic quantification, though current algorithms remain largely retrospective, insufficiently validated, and unintegrated into routine workflows.
PICO
P
Population
Cardiovascular disease
I
Intervention / Comparator
Artificial intelligence, wearable, and implantable cardiac technologies
Limitations
- Evidence maturity, diagnostic performance, and implementation readiness remain highly variable
- Wearable clinical value is limited by false-positive alerts, user dependence, signal constraints, and downstream workflow burden
- Many AI applications remain retrospective, insufficiently validated, or highly dependent on local workflows
- Many applications remain retrospective, insufficiently validated, or highly dependent on local workflows
- Technical capability often exceeds demonstrated real-world utility
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We're seeing remarkable advancements in AI's ability to assist with diagnosis, assess cardiovascular risk and even help with patient communication. However, we must balance our enthusiasm with a rigorous approach to validation and implementation.”
“One of the issues is that AI tools, particularly large language models, are continuously receiving new input and are learning at the same time as they are acting—making them difficult to validate. This means we need to be careful and not use new technologies without proper verification, which involves running clinical trials to prove these tools properly work for a specific task, publishing the results and alerting the community of new developments.”
“I also showed the results to cardiologist Eric Topol of the Scripps Research Institute, an expert on both longevity and the potential of AI in medicine. 'It's baseless,' he said. 'This is not ready for any medical advice.'”
Implication
While AI and wearable/implantable cardiac technologies show promise, their clinical integration requires stronger validation, transparent reporting, and careful workflow integration.
Abstract
Cardiac technologies have evolved from conventional diagnostic tools to implantable, wearable, and increasingly AI-enabled systems that support more continuous cardiovascular assessment. However, this transition should not be interpreted as a uniform improvement in clinical care. This critical narrative review examines contemporary cardiac monitoring and therapeutic technologies, with particular emphasis on implantable devices, wearable platforms, and artificial intelligence (AI) applications in rhythm analysis, imaging, and risk prediction. Across these domains, evidence maturity, diagnostic performance, and implementation readiness remain highly variable. Implantable systems provide the most continuous monitoring and, in selected cases, therapeutic intervention, but their benefit depends on indication, patient selection, complication profile, and follow-up infrastructure. Wearable technologies broaden ambulatory surveillance, especially for rhythm assessment, yet their clinical value is limited by false-positive alerts, user dependence, signal constraints, and downstream workflow burden. AI has shown promise in ECG interpretation, echocardiographic quantification, and analysis of longitudinal device-derived data, but many applications remain retrospective, insufficiently validated, or highly dependent on local workflows. A recurring limitation across next-generation cardiac systems is that technical capability often exceeds demonstrated real-world utility. Future progress will depend not only on innovation, but also on stronger validation, careful integration into clinical pathways, transparent reporting, and closer attention to interoperability, reimbursement, and data governance.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Mutlag et al. (2026) conducted a review in Cardiovascular disease. Artificial intelligence, wearable, and implantable cardiac technologies was evaluated. Next-generation cardiac systems, including AI, wearables, and implantables, show promise in monitoring and diagnostics, but their technical capabilities often exceed demonstrated real-world utility.